PF-Atlas › Clinical Trials › NCT01766817
Safety and Efficacy of a Lysophosphatidic Acid Receptor Antagonist in Idiopathic Pulmonary Fibrosis
BMS-986020 · Phase 2
Registry ID
NCT01766817
Phase
Phase 2
Status
Completed
Drug / intervention
BMS-986020
Sponsor
Bristol-Myers Squibb
Start
2013-01-31
Enrollment
325
Locations
72
About this trial
The purpose of this study is to determine if study drug (BMS-986020) dose of 600 mg once daily or 600 mg twice daily for 26 weeks compared with placebo will reduce the decline in forced vital capacity (FVC) and will be well tolerated in subjects with idiopathic pulmonary fibrosis (IPF).
Explore related
Medical disclaimer. This page summarizes public trial data for NCT01766817 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.